Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.

ABSTRACT:

Background

The optimal number of chemotherapy courses for low-risk (LR) pediatric acute myeloid leukemia (AML) is not known.

Objective

To compare outcomes for four (21.6 g/m² cytarabine) versus five (45.6 g/m² cytarabine) chemotherapy courses for LR-AML using data from Children's Oncology Group (COG) AAML0531 and AAML1031.

Methods

We compared relapse risk (RR), disease-free survival (DFS), and overall survival (OS), and the differential impact in LR subgroups for patients receiving four versus five chemotherapy courses. Cox (OS and DFS) and risk (RR) regressions were used to estimate hazard ratios (HR) to compare outcomes.

Results

A total of 923 LR-AML patients were included; 21% received five courses. Overall, LR-AML patients who received

SUBMITTER: Getz KD 

PROVIDER: S-EPMC8919970 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature